Trial intelligence / Profile preview

Cyclosporine vs methotrexate for moderate-to-severe atopic dermatitis in children and adolescents

2023-509759-15-00Phase 3Authorised

Sponsor: Medical University of Lodz
Start: Dec 2024
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial in atopic dermatitis (AD) comparing Cyclosporine with Methotrexate (2 arms). Primary endpoint: EASI75 at week 32. Planned start Dec 2024; status: authorised.

Drugs

cyclosporinemethotrexate

Conditions

atopic dermatitis (AD)

Beyond the preview

Go deeper on 2023-509759-15-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2023-509759-15-00.